Devonian Health GroupDVHGF 49 EPS without NRI is $-1.61 as of Apr. 2026. GuruFocus rates DVHGF with a GF Score™ of 49/100 and a GF Value™ of $1.99 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,167 Biotechnology companies, Devonian Health Group ranks better than 61.27% on this metric.
Devonian Health Group's earnings per share without non-recurring items for the
three
months ended in Apr. 2026 was $-0.51.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Apr. 2026 was $-1.61.
During the past 12 months, Devonian Health Group's average earnings per share (NRI) Growth Rate was -1419.50% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 25.50% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 26.70% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 15.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Devonian Health Group's EPS without NRI or its related term are showing as below:
DVHGF'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -0.1 Med: 15.05 Max: 29.9
Current: 25.5
During the past 12 years, Devonian Health Group's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 29.90% per year. The lowest was -0.10% per year. And the median was 15.05% per year.
DVHGF's 3-Year EPS without NRI Growth Rate is ranked better than 61.27% of 1167
companies
in the Biotechnology industry
Industry Median: 16.2
vs DVHGF: 25.50
Devonian Health Group (OTCPK:DVHGF) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Devonian Health Group EPS without NRI Related Terms
Devonian Health Group EPS without NRI Historical Data
* Premium members only.
The historical data trend for Devonian Health Group's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DVHGF vs VRTX, REGN, ALNY: EPS without NRI Comparison
For the Biotechnology subindustry, Devonian Health Group's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.61
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Devonian Health Group (DVHGF) has a EPS without NRI of $-1.61 as of Apr. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Devonian Health Group and its competitors. According to the industry distribution chart, Devonian Health Group ranks #452 out of 1167 companies in the Biotechnology industry, placing it in the top 38.7%.
Is Devonian Health Group's EPS without NRI too high?
Devonian Health Group's current EPS without NRI is $-1.61. Based on the distribution chart, Devonian Health Group ranks #452 out of 1167 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Devonian Health Group has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #452 out of 1167 companies for EPS without NRI. This puts Devonian Health Group in the upper half of its industry. The industry median EPS without NRI is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.20, based on 1,167 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Devonian Health Group and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Devonian Health Group's current EPS without NRI is $-1.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.99, compared to a current price of $7.00 — trading 251.8% above its estimated fair value. The current EPS without NRI is $-1.61. Devonian Health Group's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current EPS without NRI is $-1.61 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devonian Health Group (DVHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued.
The current stock price of $7.00 is trading 251.8% above its estimated GF Value™ of $1.99.
GuruFocus considers Devonian Health Group to be Significantly Overvalued.
Key valuation signals for DVHGF:
EPS without NRI: $-1.61
GF Value™: $1.99 vs. price of $7.00 (251.8% above fair value)
No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
49GF Score
Get the complete analysis for DVHGF
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVHGF has been successfully added to your 
